Sanofi pays $3 million milestone to ImmunoGen on start of SAR3419 Ph II testing; FDA accepts Aubagio filing

21 October 2011

US biotech firm ImmunoGen (Nasdaq: IMGN) says that SAR3419 has started Phase II testing, which triggers a $3 million milestone payment from French drug major Sanofi (Euronext: SAN) as part of a broader collaboration between the companies.

SAR3419 is a potential new treatment for CD19+ non-Hodgkin’s lymphoma (NHL) and other B-cell malignancies. In Phase I testing, this TAP compound demonstrated activity across an array of NHL histological subtypes in patients with recurrent disease. It also demonstrated activity in patients with both rituximab (Rituximab-refractory and responsive disease. SAR3419 was found to be generally well tolerated with a notable lack of significant myelosuppression.

Sanofi’s Phase II testing will focus on evaluating SAR3419 as a treatment for diffuse large B-cell lymphoma (DLBCL) and for B-cell acute lymphoblastic lymphoma (B-ALL). Currently, there are limited treatment options for B-ALL and also for DLBCL that has failed to respond to front-line therapy or recurred after treatment. DLBCL is the most common type of NHL, accounting for approximately one-third of all cases, while B-ALL accounts for a similar percentage of acute leukemia cases.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology